Ocean Biomedical Inc. has discovered bispecific antibodies that target Chitinase 3-like-1 (CHI3L1) and immune checkpoint inhibitors, killing glioblastoma cells and melanoma cells, and blocking the metastasis of malignant melanoma cells to the lung by over 90%.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has disclosed isocitrate dehydrogenase (NADP+) (IDPc, IDH1) mutant inhibitors reported to be useful for the treatment of cancer.
A Harvard Medical School research team developed a bifunctional therapeutic vaccine strategy by transforming living tumor cells into a potent agent with direct tumor killing and immunostimulatory abilities.
Transcode Therapeutics Inc. has received clearance from the FDA to proceed with a first-in-human phase 0 trial of TTX-MC138 in cancer patients with advanced solid tumors. A single dose of radiolabeled TTX-MC138 will be followed by noninvasive PET-MRI to quantify the amount of radiolabeled TTX-MC138 delivered to metastatic lesions.
